Report Code: CMI43212

Published Date: March 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 7.5%
5.8B
2023
6.2B
2024
12.1B
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Invitae Corporation
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Hereditary Cancer Testing Market is expected to record a CAGR of 7.5% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 6.2 Billion. By 2033, the valuation is anticipated to reach USD 12.1 Billion.

The hereditary cancer testing market encompasses the diagnostic testing services and technologies utilized to assess an individual’s genetic predisposition to hereditary cancers. It involves the analysis of genetic mutations and variations associated with an increased risk of developing specific types of cancer.

This market serves individuals with a family history of cancer, as well as those without prior cancer diagnoses seeking to understand their genetic susceptibility.

Key components include genetic counseling, testing methodologies such as next-generation sequencing, and the interpretation of test results to guide personalized cancer risk assessment, prevention, and management strategies.

Hereditary Cancer Testing Market – Significant Growth Factors

The Hereditary Cancer Testing Market presents significant growth opportunities due to several factors:

  • Increasing Cancer Incidence: The rising prevalence of cancer worldwide, coupled with growing awareness of hereditary factors contributing to cancer risk, drives demand for hereditary cancer testing. As individuals seek to understand their genetic predisposition to cancer, the demand for testing services increases.
  • Advancements in Genetic Testing Technologies: Ongoing advancements in genetic testing technologies, such as next-generation sequencing (NGS) and multiplex PCR, enable more accurate and comprehensive analysis of genetic mutations associated with hereditary cancers. These technological innovations expand the capabilities and accessibility of hereditary cancer testing.
  • Rising Adoption of Precision Medicine: The shift towards precision medicine approaches in cancer care, which aim to tailor treatment strategies based on an individual’s genetic profile, fuels demand for hereditary cancer testing.
  • Government Support and Initiatives: Government initiatives aimed at promoting cancer awareness, prevention, and early detection, along with regulatory frameworks supporting genetic testing services, drive market growth. Funding for research, public health programs, and genetic counseling services, as well as regulatory guidelines ensuring quality standards and patient confidentiality, contribute to the expansion of hereditary cancer testing services.
  • Expansion of Direct-to-Consumer Testing: The growing popularity of direct-to-consumer (DTC) genetic testing services presents an opportunity for market expansion. DTC testing allows individuals to access genetic testing services without a healthcare provider’s involvement, potentially increasing the reach and accessibility of hereditary cancer testing to broader populations.

Hereditary Cancer Testing Market – Mergers and Acquisitions

The Hereditary Cancer Testing Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Hereditary Cancer Testing Market include:

  • In 2022, Helio Genomics, in partnership with Fulgent Genetics, secured a new Category I CPT code from the AMA for HelioLiver, enhancing the adoption of advanced surveillance tests for liver cancer in the U.S. This achievement expands the company’s product portfolio and market reach.
  • In 2022, Illumina, Inc. unveiled an in vitro diagnostic (IVD) kit, a cancer RNA sequencer, expanding its sequencing product line. The launch, coupled with post-market approval, signifies linear market growth, underlining the company’s commitment to advancing cancer diagnostics and improving patient care.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Hereditary Cancer Testing Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Hereditary Cancer Testing Market Smart Healthcare Products Market mHealth Market
CAGR 7.5% (Approx) CAGR 12.78% (Approx) CAGR 17.6% (Approx)
USD 12.1 Billion by 2033 USD 485.71 Billion by 2032 USD 374.6 Billion by 2032

Hereditary Cancer Testing Market – Significant Threats

The Hereditary Cancer Testing Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Regulatory Challenges: Stringent regulatory requirements for genetic testing, including compliance with data privacy regulations, quality assurance standards, and reimbursement policies, pose challenges for market entry and expansion. Compliance with regulatory frameworks and obtaining necessary approvals can be time-consuming and costly for companies operating in the hereditary cancer testing market.
  • Genetic Counseling Shortage: The shortage of trained genetic counselors, who play a crucial role in interpreting test results, providing risk assessment, and guiding patients in making informed decisions, poses a threat to the scalability and accessibility of hereditary cancer testing services. Limited access to genetic counseling services may hinder patient understanding, compliance, and satisfaction with testing programs.
  • Ethical and Privacy Concerns: Ethical considerations surrounding genetic testing, such as concerns about the use of genetic information for discriminatory purposes, privacy breaches, and the potential psychological impact of test results on individuals and their families, pose threats to market acceptance and adoption of hereditary cancer testing. Addressing ethical and privacy concerns is essential to build trust and confidence in testing services.
  • Limited Insurance Coverage: Limited insurance coverage and reimbursement for hereditary cancer testing services, particularly for individuals without a personal or family history of cancer, pose barriers to market growth. High out-of-pocket costs for testing may deter individuals from undergoing genetic testing, especially in regions with inadequate insurance coverage or reimbursement policies for genetic testing services.

Global Hereditary Cancer Testing Market 2024–2033 (By Test Type)

www.custommarketinsight.com

Category-Wise Insights:

By Disease Type

  • Hereditary Breast & Ovarian Cancer Syndrome: Involves genetic mutations associated with increased breast and ovarian cancer risk. Market trends include advancements in BRCA gene testing technologies and expanding access to genetic counseling services for individuals with a family history of breast or ovarian cancer.
  • Cowden Syndrome: A rare genetic disorder characterized by multiple non-cancerous tumor growths and an increased risk of breast, thyroid, and other cancers. Market trends include the integration of genetic testing for PTEN gene mutations into comprehensive hereditary cancer testing panels and increased awareness among healthcare providers.
  • Lynch Syndrome: Also known as hereditary nonpolyposis colorectal cancer (HNPCC), Lynch syndrome is characterized by an increased risk of colorectal, endometrial, and other cancers. Market trends include the development of multi-gene panel testing for Lynch syndrome-associated gene mutations and the integration of tumor testing to identify individuals at risk.
  • Hereditary Leukemia and Hematologic Malignancies Syndromes: Include genetic predispositions to various types of leukemia and hematologic malignancies. Market trends include advancements in genetic testing technologies for hematologic cancers, such as next-generation sequencing, and the incorporation of molecular profiling into diagnostic and treatment strategies.
  • Familial Adenomatous Polyposis (FAP): A hereditary condition characterized by the development of numerous colorectal polyps and an increased risk of colorectal cancer. Market trends include the use of genetic testing for APC gene mutations in FAP diagnosis and management, as well as the emergence of targeted therapies for individuals with FAP-associated colorectal cancer.
  • Li-Fraumeni Syndrome: A rare genetic disorder associated with an increased risk of various cancers, including breast cancer, sarcomas, and brain tumors. Market trends include the expansion of genetic testing panels to include TP53 gene mutations associated with Li-Fraumeni syndrome and increased surveillance and management strategies for individuals with a TP53 mutation.
  • Von Hippel-Lindau Disease: A rare genetic disorder characterized by the development of tumors in various organs, including the kidneys, adrenal glands, and central nervous system. Market trends include the integration of genetic testing for VHL gene mutations into comprehensive hereditary cancer testing panels and advancements in imaging technologies for tumor surveillance.
  • Multiple Endocrine Neoplasias (MEN) Syndromes: Include genetic syndromes characterized by the development of tumors in multiple endocrine glands. Market trends include the development of multi-gene panel testing for MEN-associated gene mutations and the implementation of personalized screening and management protocols for individuals with MEN syndromes.

By test Type

  • Multi Panel Set: A multi-panel set in hereditary cancer testing involves the analysis of multiple genes associated with various types of cancer susceptibility within a single test. Trends include the development of comprehensive panels covering a wide range of cancer types, enhanced accuracy through next-generation sequencing, and increasing demand for comprehensive genetic risk assessment.
  • Single Site Genetic Test: A single site genetic test focuses on detecting a specific genetic mutation or variant associated with a particular hereditary cancer syndrome. Trends include the availability of targeted tests for high-risk mutations, improved sensitivity and specificity through advanced molecular techniques, and adoption in precision medicine approaches for personalized cancer risk assessment and management.

Global Hereditary Cancer Testing Market 2024–2033 (By Diagnosis Type)

www.custommarketinsight.com

By Diagnosis Type

  • Biopsy: In the Hereditary Cancer Testing Market, biopsy involves the removal and analysis of tissue samples to identify genetic mutations associated with hereditary cancers. Trends include the integration of genetic analysis into biopsy procedures, enabling simultaneous diagnosis of cancer and genetic predisposition to hereditary cancers.
  • Imaging: Imaging techniques, such as MRI, CT scans, and ultrasound, are utilized in the Hereditary Cancer Testing Market to visualize tumor growth and assess cancer progression. Trends include the incorporation of imaging data into genetic testing algorithms, enhancing the accuracy of hereditary cancer risk assessment and treatment planning.
  • Lab Tests: Laboratory tests, including blood tests and molecular assays, are employed in the Hereditary Cancer Testing Market to detect genetic mutations indicative of hereditary cancer risk. Trends include the development of multiplex testing panels and high-throughput technologies for efficient and comprehensive genetic screening of hereditary cancer predispositions.

By Technology

  • Sequencing: In the Hereditary Cancer Testing Market, sequencing involves analyzing DNA to identify genetic mutations linked to hereditary cancers. Trends include the adoption of next-generation sequencing (NGS) technologies for comprehensive and cost-effective genetic analysis, enabling the identification of inherited cancer susceptibility genes with high accuracy and throughput.
  • Polymerase Chain Reaction (PCR): Polymerase Chain Reaction (PCR) is utilized in the Hereditary Cancer Testing Market to amplify DNA segments for the detection of genetic mutations associated with hereditary cancers. Trends include the development of multiplex PCR assays enabling simultaneous detection of multiple genetic variants, improving testing efficiency and diagnostic accuracy for hereditary cancer risk assessment.
  • Microarray: Microarray technology in the Hereditary Cancer Testing Market involves analyzing genetic variations associated with hereditary cancers using DNA microarrays. Trends include the integration of microarray platforms with high-throughput sequencing technologies, enabling comprehensive analysis of genetic markers and mutations associated with hereditary cancer predisposition, and facilitating personalized risk assessment and management strategies.

By End Users

  • Hospitals: Hospitals provide comprehensive healthcare services, including hereditary cancer testing, as part of their diagnostic and treatment offerings. Trends include the integration of genetic testing services into hospital-based oncology departments and the adoption of multidisciplinary approaches to cancer care.
  • Clinics: Clinics offer outpatient medical services, including hereditary cancer testing, to individuals seeking preventive care and diagnostic evaluations. Trends include the expansion of specialized clinics focusing on genetic counseling and testing for hereditary cancers, as well as the integration of testing services into primary care settings.
  • Laboratories: Laboratories specialize in conducting genetic testing and analysis for hereditary cancer risk assessment. Trends include advancements in testing technologies, such as next-generation sequencing (NGS) and multiplex PCR assays, to enhance the accuracy and efficiency of genetic testing services, as well as the development of automated testing platforms for high-throughput testing.
  • Radiology Centers: Radiology centers provide imaging services, such as MRI, CT scans, and X-rays, to aid in cancer diagnosis and staging. Trends include the integration of radiogenomic approaches, which correlate imaging features with genetic markers, to improve cancer risk assessment and treatment planning in individuals undergoing hereditary cancer testing.
  • Diagnostic Centers: Diagnostic centers offer a range of diagnostic services, including genetic testing for hereditary cancer risk assessment. Trends include the adoption of comprehensive testing panels covering multiple cancer susceptibility genes, as well as the implementation of standardized testing protocols and quality assurance measures to ensure accurate and reliable test results.
  • Others: This category may include specialized cancer centers, research institutions, and genetic testing companies offering direct-to-consumer testing services for hereditary cancer risk assessment. Trends include the development of novel testing methodologies, such as liquid biopsy and circulating tumor DNA analysis, to improve early detection and monitoring of hereditary cancers.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 6.2 Billion
Projected Market Size in 2033 USD 12.1 Billion
Market Size in 2023 USD 5.8 Billion
CAGR Growth Rate 7.5% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Disease Type, Test Type, Diagnosis Type, Technology, End User and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Hereditary Cancer Testing Market – Regional Analysis

The Hereditary Cancer Testing Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, trends in the Hereditary Cancer Testing Market include the widespread adoption of genetic testing services driven by a robust healthcare infrastructure, increasing awareness of hereditary cancer risk factors, and favorable reimbursement policies. Additionally, the integration of genetic testing into mainstream healthcare practices, along with advancements in testing technologies and the availability of personalized medicine approaches, contribute to market growth.
  • Europe: In Europe, trends in the Hereditary Cancer Testing Market include a growing emphasis on preventive healthcare, expanding access to genetic counseling services, and increasing adoption of population-based screening programs for hereditary cancers. Additionally, regulatory initiatives promoting standardized testing protocols, data privacy regulations, and quality assurance standards shape market dynamics. Moreover, collaborative efforts between healthcare providers, research institutions, and industry stakeholders drive innovation and market expansion.
  • Asia-Pacific: In the Asia-Pacific region, trends in the Hereditary Cancer Testing Market include rising cancer incidence rates, increasing awareness of genetic predispositions to cancer, and expanding access to healthcare services. Additionally, the adoption of telemedicine and digital health solutions facilitates access to genetic counseling and testing services in remote and underserved areas. Moreover, partnerships between international and local players drive technology transfer and market penetration in the region.
  • LAMEA (Latin America, Middle East, and Africa): In the LAMEA region, trends in the Hereditary Cancer Testing Market include growing investments in healthcare infrastructure, expanding access to genetic testing services, and rising adoption of precision medicine approaches. Additionally, cultural factors influencing attitudes towards genetic testing, regulatory challenges, and economic disparities shape market dynamics. Moreover, collaborations between public and private sector stakeholders drive awareness campaigns and capacity building initiatives in the region.

Global Hereditary Cancer Testing Market 2024–2033 (By Billion)

www.custommarketinsight.com

Competitive Landscape – Hereditary Cancer Testing Market

The Hereditary Cancer Testing Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Invitae Corporation
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Ambry Genetics Corporation
  • BioReference Laboratories Inc.
  • LabCorp
  • Qiagen N.V.
  • Roche Diagnostics
  • Color Genomics Inc.
  • Centogene AG
  • GeneDx
  • Natera Inc.
  • Foundation Medicine Inc.
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players in the Hereditary Cancer Testing Market, such as Color Genomics and Invitae Corporation, have adopted innovative approaches to enter the market by leveraging advancements in genetic testing technologies and direct-to-consumer models. They offer comprehensive testing panels and streamline testing processes, targeting both healthcare providers and consumers.

Key players dominating the market include Myriad Genetics, Quest Diagnostics, and Illumina, with established reputations, extensive testing portfolios, and strong distribution networks. These key players maintain market dominance through continuous innovation, strategic partnerships, and comprehensive service offerings catering to diverse market segments.

The Hereditary Cancer Testing Market is segmented as follows:

By Disease Type

  • Hereditary Breast & Ovarian Cancer Syndrome
  • Cowden Syndrome
  • Lynch Syndrome
  • Hereditary Leukemia and Hematologic Malignancies Syndromes
  • Familial Adenomatous Polyposis (FAP)
  • Li-Fraumeni Syndrome
  • Von Hippel-Lindau Disease
  • Multiple Endocrine Neoplasias (MEN) Syndromes

By Test Type

  • Multi Panel Set
  • Single Site Genetic Test

By Diagnosis Type

  • Biopsy
  • Imaging
  • Lab Tests

By Technology

  • Sequencing
  • Polymerase Chain Reaction (PCR)
  • Microarray

By End User

  • Hospitals
  • Clinics
  • Laboratories
  • Radiology Centers
  • Diagnostic Centers
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Hereditary Cancer Testing Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Hereditary Cancer Testing Market: snapshot
  • Chapter 3. Global Hereditary Cancer Testing Market – Industry Analysis
    • 3.1 Hereditary Cancer Testing Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Cancer Incidence
      • 3.2.2 Advancements in Genetic Testing Technologies
      • 3.2.3 Rising Adoption of Precision Medicine
      • 3.2.4 Government Support and Initiatives And Expansion of Direct-to-Consumer Testing.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Disease Type
      • 3.7.2 Market Attractiveness Analysis By Test Type
      • 3.7.3 Market Attractiveness Analysis By Diagnosis Type
      • 3.7.4 Market Attractiveness Analysis By Technology
      • 3.7.5 Market Attractiveness Analysis By End User
  • Chapter 4. Global Hereditary Cancer Testing Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Hereditary Cancer Testing Market: Company Market Share, 2024
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Hereditary Cancer Testing Market – Disease Type Analysis
    • 5.1 Global Hereditary Cancer Testing Market Overview: By Disease Type
      • 5.1.1 Global Hereditary Cancer Testing Market Share, By Disease Type, 2024 and – 2033
    • 5.2 Hereditary Breast & Ovarian Cancer Syndrome
      • 5.2.1 Global Hereditary Cancer Testing Market by Hereditary Breast & Ovarian Cancer Syndrome, 2024 – 2033 (USD Billion)
    • 5.3 Cowden Syndrome
      • 5.3.1 Global Hereditary Cancer Testing Market by Cowden Syndrome, 2024 – 2033 (USD Billion)
    • 5.4 Lynch Syndrome
      • 5.4.1 Global Hereditary Cancer Testing Market by Lynch Syndrome, 2024 – 2033 (USD Billion)
    • 5.5 Hereditary Leukemia and Hematologic Malignancies Syndromes
      • 5.5.1 Global Hereditary Cancer Testing Market by Hereditary Leukemia and Hematologic Malignancies Syndromes, 2024 – 2033 (USD Billion)
    • 5.6 Familial Adenomatous Polyposis (FAP)
      • 5.6.1 Global Hereditary Cancer Testing Market by Familial Adenomatous Polyposis (FAP), 2024 – 2033 (USD Billion)
    • 5.7 Li-Fraumeni Syndrome
      • 5.7.1 Global Hereditary Cancer Testing Market by Li-Fraumeni Syndrome, 2024 – 2033 (USD Billion)
    • 5.8 Von Hippel-Lindau Disease
      • 5.8.1 Global Hereditary Cancer Testing Market by Von Hippel-Lindau Disease, 2024 – 2033 (USD Billion)
    • 5.9 Multiple Endocrine Neoplasias (MEN) Syndromes
      • 5.9.1 Global Hereditary Cancer Testing Market by Multiple Endocrine Neoplasias (MEN) Syndromes, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Hereditary Cancer Testing Market – Test Type Analysis
    • 6.1 Global Hereditary Cancer Testing Market Overview: By Test Type
      • 6.1.1 Global Hereditary Cancer Testing Market Share, By Test Type, 2024 and – 2033
    • 6.2 Multi Panel Set
      • 6.2.1 Global Hereditary Cancer Testing Market by Multi Panel Set, 2024 – 2033 (USD Billion)
    • 6.3 Single Site Genetic Test
      • 6.3.1 Global Hereditary Cancer Testing Market by Single Site Genetic Test, 2024 – 2033 (USD Billion)
  • Chapter 7. Global Hereditary Cancer Testing Market – Diagnosis Type Analysis
    • 7.1 Global Hereditary Cancer Testing Market Overview: By Diagnosis Type
      • 7.1.1 Global Hereditary Cancer Testing Market Share, By Diagnosis Type, 2024 and – 2033
    • 7.2 Biopsy
      • 7.2.1 Global Hereditary Cancer Testing Market by Biopsy, 2024 – 2033 (USD Billion)
    • 7.3 Imaging
      • 7.3.1 Global Hereditary Cancer Testing Market by Imaging, 2024 – 2033 (USD Billion)
    • 7.4 Lab Tests
      • 7.4.1 Global Hereditary Cancer Testing Market by Lab Tests, 2024 – 2033 (USD Billion)
  • Chapter 8. Global Hereditary Cancer Testing Market – Technology Analysis
    • 8.1 Global Hereditary Cancer Testing Market Overview: By Technology
      • 8.1.1 Global Hereditary Cancer Testing Market Share, By Technology, 2024 and – 2033
    • 8.2 Sequencing
      • 8.2.1 Global Hereditary Cancer Testing Market by Sequencing, 2024 – 2033 (USD Billion)
    • 8.3 Polymerase Chain Reaction (PCR)
      • 8.3.1 Global Hereditary Cancer Testing Market by Polymerase Chain Reaction (PCR), 2024 – 2033 (USD Billion)
    • 8.4 Microarray
      • 8.4.1 Global Hereditary Cancer Testing Market by Microarray, 2024 – 2033 (USD Billion)
  • Chapter 9. Global Hereditary Cancer Testing Market – End User Analysis
    • 9.1 Global Hereditary Cancer Testing Market Overview: By End User
      • 9.1.1 Global Hereditary Cancer Testing Market Share, By End User, 2024 and – 2033
    • 9.2 Hospitals
      • 9.2.1 Global Hereditary Cancer Testing Market by Hospitals, 2024 – 2033 (USD Billion)
    • 9.3 Clinics
      • 9.3.1 Global Hereditary Cancer Testing Market by Clinics, 2024 – 2033 (USD Billion)
    • 9.4 Laboratories
      • 9.4.1 Global Hereditary Cancer Testing Market by Laboratories, 2024 – 2033 (USD Billion)
    • 9.5 Radiology Centers
      • 9.5.1 Global Hereditary Cancer Testing Market by Radiology Centers, 2024 – 2033 (USD Billion)
    • 9.6 Diagnostic Centers
      • 9.6.1 Global Hereditary Cancer Testing Market by Diagnostic Centers, 2024 – 2033 (USD Billion)
    • 9.7 Others
      • 9.7.1 Global Hereditary Cancer Testing Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 10. Hereditary Cancer Testings Market – Regional Analysis
    • 10.1 Global Hereditary Cancer Testings Market Regional Overview
    • 10.2 Global Hereditary Cancer Testings Market Share, by Region, 2024 & – 2033 (USD Billion)
    • 10.3. North America
      • 10.3.1 North America Hereditary Cancer Testings Market, 2024 – 2033 (USD Billion)
        • 10.3.1.1 North America Hereditary Cancer Testings Market, by Country, 2024 – 2033 (USD Billion)
    • 10.4 North America Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033
      • 10.4.1 North America Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033 (USD Billion)
    • 10.5 North America Hereditary Cancer Testings Market, by Test Type, 2024 – 2033
      • 10.5.1 North America Hereditary Cancer Testings Market, by Test Type, 2024 – 2033 (USD Billion)
    • 10.6 North America Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033
      • 10.6.1 North America Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033 (USD Billion)
    • 10.7 North America Hereditary Cancer Testings Market, by Technology, 2024 – 2033
      • 10.7.1 North America Hereditary Cancer Testings Market, by Technology, 2024 – 2033 (USD Billion)
    • 10.8 North America Hereditary Cancer Testings Market, by End User, 2024 – 2033
      • 10.8.1 North America Hereditary Cancer Testings Market, by End User, 2024 – 2033 (USD Billion)
    • 10.9. Europe
      • 10.9.1 Europe Hereditary Cancer Testings Market, 2024 – 2033 (USD Billion)
        • 10.9.1.1 Europe Hereditary Cancer Testings Market, by Country, 2024 – 2033 (USD Billion)
    • 10.10 Europe Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033
      • 10.10.1 Europe Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033 (USD Billion)
    • 10.11 Europe Hereditary Cancer Testings Market, by Test Type, 2024 – 2033
      • 10.11.1 Europe Hereditary Cancer Testings Market, by Test Type, 2024 – 2033 (USD Billion)
    • 10.12 Europe Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033
      • 10.12.1 Europe Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033 (USD Billion)
    • 10.13 Europe Hereditary Cancer Testings Market, by Technology, 2024 – 2033
      • 10.13.1 Europe Hereditary Cancer Testings Market, by Technology, 2024 – 2033 (USD Billion)
    • 10.14 Europe Hereditary Cancer Testings Market, by End User, 2024 – 2033
      • 10.14.1 Europe Hereditary Cancer Testings Market, by End User, 2024 – 2033 (USD Billion)
    • 10.15. Asia Pacific
      • 10.15.1 Asia Pacific Hereditary Cancer Testings Market, 2024 – 2033 (USD Billion)
        • 10.15.1.1 Asia Pacific Hereditary Cancer Testings Market, by Country, 2024 – 2033 (USD Billion)
    • 10.16 Asia Pacific Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033
      • 10.16.1 Asia Pacific Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033 (USD Billion)
    • 10.17 Asia Pacific Hereditary Cancer Testings Market, by Test Type, 2024 – 2033
      • 10.17.1 Asia Pacific Hereditary Cancer Testings Market, by Test Type, 2024 – 2033 (USD Billion)
    • 10.18 Asia Pacific Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033
      • 10.18.1 Asia Pacific Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033 (USD Billion)
    • 10.19 Asia Pacific Hereditary Cancer Testings Market, by Technology, 2024 – 2033
      • 10.19.1 Asia Pacific Hereditary Cancer Testings Market, by Technology, 2024 – 2033 (USD Billion)
    • 10.20 Asia Pacific Hereditary Cancer Testings Market, by End User, 2024 – 2033
      • 10.20.1 Asia Pacific Hereditary Cancer Testings Market, by End User, 2024 – 2033 (USD Billion)
    • 10.21. Latin America
      • 10.21.1 Latin America Hereditary Cancer Testings Market, 2024 – 2033 (USD Billion)
        • 10.21.1.1 Latin America Hereditary Cancer Testings Market, by Country, 2024 – 2033 (USD Billion)
    • 10.22 Latin America Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033
      • 10.22.1 Latin America Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033 (USD Billion)
    • 10.23 Latin America Hereditary Cancer Testings Market, by Test Type, 2024 – 2033
      • 10.23.1 Latin America Hereditary Cancer Testings Market, by Test Type, 2024 – 2033 (USD Billion)
    • 10.24 Latin America Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033
      • 10.24.1 Latin America Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033 (USD Billion)
    • 10.25 Latin America Hereditary Cancer Testings Market, by Technology, 2024 – 2033
      • 10.25.1 Latin America Hereditary Cancer Testings Market, by Technology, 2024 – 2033 (USD Billion)
    • 10.26 Latin America Hereditary Cancer Testings Market, by End User, 2024 – 2033
      • 10.26.1 Latin America Hereditary Cancer Testings Market, by End User, 2024 – 2033 (USD Billion)
    • 10.27. The Middle-East and Africa
      • 10.27.1 The Middle-East and Africa Hereditary Cancer Testings Market, 2024 – 2033 (USD Billion)
        • 10.27.1.1 The Middle-East and Africa Hereditary Cancer Testings Market, by Country, 2024 – 2033 (USD Billion)
    • 10.28 The Middle-East and Africa Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033
      • 10.28.1 The Middle-East and Africa Hereditary Cancer Testings Market, by Disease Type, 2024 – 2033 (USD Billion)
    • 10.29 The Middle-East and Africa Hereditary Cancer Testings Market, by Test Type, 2024 – 2033
      • 10.29.1 The Middle-East and Africa Hereditary Cancer Testings Market, by Test Type, 2024 – 2033 (USD Billion)
    • 10.30 The Middle-East and Africa Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033
      • 10.30.1 The Middle-East and Africa Hereditary Cancer Testings Market, by Diagnosis Type, 2024 – 2033 (USD Billion)
    • 10.31 The Middle-East and Africa Hereditary Cancer Testings Market, by Technology, 2024 – 2033
      • 10.31.1 The Middle-East and Africa Hereditary Cancer Testings Market, by Technology, 2024 – 2033 (USD Billion)
    • 10.32 The Middle-East and Africa Hereditary Cancer Testings Market, by End User, 2024 – 2033
      • 10.32.1 The Middle-East and Africa Hereditary Cancer Testings Market, by End User, 2024 – 2033 (USD Billion)
  • Chapter 11. Company Profiles
    • 11.1 Myriad Genetics Inc.
      • 11.1.1 Overview
      • 11.1.2 Financials
      • 11.1.3 Product Portfolio
      • 11.1.4 Business Strategy
      • 11.1.5 Recent Developments
    • 11.2 Quest Diagnostics
      • 11.2.1 Overview
      • 11.2.2 Financials
      • 11.2.3 Product Portfolio
      • 11.2.4 Business Strategy
      • 11.2.5 Recent Developments
    • 11.3 Invitae Corporation
      • 11.3.1 Overview
      • 11.3.2 Financials
      • 11.3.3 Product Portfolio
      • 11.3.4 Business Strategy
      • 11.3.5 Recent Developments
    • 11.4 Illumina Inc.
      • 11.4.1 Overview
      • 11.4.2 Financials
      • 11.4.3 Product Portfolio
      • 11.4.4 Business Strategy
      • 11.4.5 Recent Developments
    • 11.5 Thermo Fisher Scientific Inc.
      • 11.5.1 Overview
      • 11.5.2 Financials
      • 11.5.3 Product Portfolio
      • 11.5.4 Business Strategy
      • 11.5.5 Recent Developments
    • 11.6 Ambry Genetics Corporation
      • 11.6.1 Overview
      • 11.6.2 Financials
      • 11.6.3 Product Portfolio
      • 11.6.4 Business Strategy
      • 11.6.5 Recent Developments
    • 11.7 BioReference Laboratories Inc.
      • 11.7.1 Overview
      • 11.7.2 Financials
      • 11.7.3 Product Portfolio
      • 11.7.4 Business Strategy
      • 11.7.5 Recent Developments
    • 11.8 LabCorp
      • 11.8.1 Overview
      • 11.8.2 Financials
      • 11.8.3 Product Portfolio
      • 11.8.4 Business Strategy
      • 11.8.5 Recent Developments
    • 11.9 Qiagen N.V.
      • 11.9.1 Overview
      • 11.9.2 Financials
      • 11.9.3 Product Portfolio
      • 11.9.4 Business Strategy
      • 11.9.5 Recent Developments
    • 11.10 Roche Diagnostics
      • 11.10.1 Overview
      • 11.10.2 Financials
      • 11.10.3 Product Portfolio
      • 11.10.4 Business Strategy
      • 11.10.5 Recent Developments
    • 11.11 Color Genomics Inc.
      • 11.11.1 Overview
      • 11.11.2 Financials
      • 11.11.3 Product Portfolio
      • 11.11.4 Business Strategy
      • 11.11.5 Recent Developments
    • 11.12 Centogene AG
      • 11.12.1 Overview
      • 11.12.2 Financials
      • 11.12.3 Product Portfolio
      • 11.12.4 Business Strategy
      • 11.12.5 Recent Developments
    • 11.13 GeneDx
      • 11.13.1 Overview
      • 11.13.2 Financials
      • 11.13.3 Product Portfolio
      • 11.13.4 Business Strategy
      • 11.13.5 Recent Developments
    • 11.14 Natera Inc.
      • 11.14.1 Overview
      • 11.14.2 Financials
      • 11.14.3 Product Portfolio
      • 11.14.4 Business Strategy
      • 11.14.5 Recent Developments
    • 11.15 Foundation Medicine Inc.
      • 11.15.1 Overview
      • 11.15.2 Financials
      • 11.15.3 Product Portfolio
      • 11.15.4 Business Strategy
      • 11.15.5 Recent Developments
    • 11.16 Others.
      • 11.16.1 Overview
      • 11.16.2 Financials
      • 11.16.3 Product Portfolio
      • 11.16.4 Business Strategy
      • 11.16.5 Recent Developments
List Of Figures

Figures No 1 to 42

List Of Tables

Tables No 1 to 127

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Invitae Corporation
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Ambry Genetics Corporation
  • BioReference Laboratories Inc.
  • LabCorp
  • Qiagen N.V.
  • Roche Diagnostics
  • Color Genomics Inc.
  • Centogene AG
  • GeneDx
  • Natera Inc.
  • Foundation Medicine Inc.
  • Others

FAQs

The key factors driving the Market are Increasing Cancer Incidence, Advancements in Genetic Testing Technologies, Rising Adoption of Precision Medicine, Government Support and Initiatives And Expansion of Direct-to-Consumer Testing.

The “Hereditary Breast & Ovarian Cancer Syndrome” category dominated the market in 2023.

The key players in the market are Myriad Genetics Inc., Quest Diagnostics, Invitae Corporation, Illumina Inc., Thermo Fisher Scientific Inc., Ambry Genetics Corporation, BioReference Laboratories Inc., LabCorp, Qiagen N.V., Roche Diagnostics, Color Genomics Inc., Centogene AG, GeneDx, Natera Inc., Foundation Medicine Inc., Others.

“North America” had the largest share in the Hereditary Cancer Testing Market.

The global market is projected to grow at a CAGR of 7.5% during the forecast period, 2024-2033.

The Hereditary Cancer Testing Market size was valued at USD 6.2 Billion in 2024.

PURCHASE OPTIONS

$

3990


$

4990


$

5990


$

2290


$

2390

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • Report in your Language.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Report in your Language.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • In-Depth Company Profiles.
  • SWOT Analysis.
  • Identify your Competitors.
  • Recent Development Analysis.
  • Competitor Pricing Strategies.
  • Competitor Marketing Strategies.
  • Competitor Positioning and Messaging.
  • Competitor Product’s Strengths.
  • Free 20% or 10 Hours of Customisation.
  • 15% Discount on your Next Purchase.
  • Upgradable to other licenses.
  • PDF Format.
  • Permission to Print the Report.

Want to customize this report?
100% FREE CUSTOMIZATION!